These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 26984268)

  • 1. CODV-Ig, a universal bispecific tetravalent and multifunctional immunoglobulin format for medical applications.
    Steinmetz A; Vallée F; Beil C; Lange C; Baurin N; Beninga J; Capdevila C; Corvey C; Dupuy A; Ferrari P; Rak A; Wonerow P; Kruip J; Mikol V; Rao E
    MAbs; 2016 Jul; 8(5):867-78. PubMed ID: 26984268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generation of dual-variable-domain immunoglobulin molecules for dual-specific targeting.
    Gu J; Ghayur T
    Methods Enzymol; 2012; 502():25-41. PubMed ID: 22208980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pre-clinical development of a novel CD3-CD123 bispecific T-cell engager using cross-over dual-variable domain (CODV) format for acute myeloid leukemia (AML) treatment.
    Bonnevaux H; Guerif S; Albrecht J; Jouannot E; De Gallier T; Beil C; Lange C; Leuschner WD; Schneider M; Lemoine C; Caron A; Amara C; Barrière C; Siavellis J; Bardet V; Luna E; Agrawal P; Drake DR; Rao E; Wonerow P; Carrez C; Blanc V; Hsu K; Wiederschain D; Fraenkel PG; Virone-Oddos A
    Oncoimmunology; 2021; 10(1):1945803. PubMed ID: 34484869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insertion of scFv into the hinge domain of full-length IgG1 monoclonal antibody results in tetravalent bispecific molecule with robust properties.
    Bezabeh B; Fleming R; Fazenbaker C; Zhong H; Coffman K; Yu XQ; Leow CC; Gibson N; Wilson S; Stover CK; Wu H; Gao C; Dimasi N
    MAbs; 2017; 9(2):240-256. PubMed ID: 27981887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
    Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
    MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diabody-Ig: a novel platform for the generation of multivalent and multispecific antibody molecules.
    Seifert O; Rau A; Beha N; Richter F; Kontermann RE
    MAbs; 2019 Jul; 11(5):919-929. PubMed ID: 30951400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics.
    Asano R; Shimomura I; Konno S; Ito A; Masakari Y; Orimo R; Taki S; Arai K; Ogata H; Okada M; Furumoto S; Onitsuka M; Omasa T; Hayashi H; Katayose Y; Unno M; Kudo T; Umetsu M; Kumagai I
    MAbs; 2014; 6(5):1243-54. PubMed ID: 25517309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic assessment of SEED: a new engineered antibody platform designed to generate mono- and bispecific antibodies.
    Muda M; Gross AW; Dawson JP; He C; Kurosawa E; Schweickhardt R; Dugas M; Soloviev M; Bernhardt A; Fischer D; Wesolowski JS; Kelton C; Neuteboom B; Hock B
    Protein Eng Des Sel; 2011 May; 24(5):447-54. PubMed ID: 21498564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Guiding bispecific monovalent antibody formation through proteolysis of IgG1 single-chain.
    Dimasi N; Fleming R; Sachsenmeier KF; Bezabeh B; Hay C; Wu J; Sult E; Rajan S; Zhuang L; Cariuk P; Buchanan A; Bowen MA; Wu H; Gao C
    MAbs; 2017 Apr; 9(3):438-454. PubMed ID: 28055299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and Validation of a Novel Generic Platform for the Production of Tetravalent IgG1-like Bispecific Antibodies.
    Golay J; Choblet S; Iwaszkiewicz J; Cérutti P; Ozil A; Loisel S; Pugnière M; Ubiali G; Zoete V; Michielin O; Berthou C; Kadouche J; Mach JP; Duonor-Cérutti M
    J Immunol; 2016 Apr; 196(7):3199-211. PubMed ID: 26921308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generation of Fabs-in-tandem immunoglobulin molecules for dual-specific targeting.
    Gong S; Wu C
    Methods; 2019 Feb; 154():87-92. PubMed ID: 30081078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of tetravalent IgG1 dual targeting IGF-1R-EGFR antibodies with potent tumor inhibition.
    Croasdale R; Wartha K; Schanzer JM; Kuenkele KP; Ries C; Mayer K; Gassner C; Wagner M; Dimoudis N; Herter S; Jaeger C; Ferrara C; Hoffmann E; Kling L; Lau W; Staack RF; Heinrich J; Scheuer W; Stracke J; Gerdes C; Brinkmann U; Umana P; Klein C
    Arch Biochem Biophys; 2012 Oct; 526(2):206-18. PubMed ID: 22464987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An end-to-end automated platform process for high-throughput engineering of next-generation multi-specific antibody therapeutics.
    Furtmann N; Schneider M; Spindler N; Steinmann B; Li Z; Focken I; Meyer J; Dimova D; Kroll K; Leuschner WD; Debeaumont A; Mathieu M; Lange C; Dittrich W; Kruip J; Schmidt T; Birkenfeld J
    MAbs; 2021; 13(1):1955433. PubMed ID: 34382900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Bispecific antibodies: what future?].
    Pèlegrin A; Robert B
    Med Sci (Paris); 2009 Dec; 25(12):1155-8. PubMed ID: 20035697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Engineering therapeutic bispecific antibodies using CrossMab technology.
    Klein C; Schaefer W; Regula JT; Dumontet C; Brinkmann U; Bacac M; Umaña P
    Methods; 2019 Feb; 154():21-31. PubMed ID: 30453028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. bisFabs: Tools for rapidly screening hybridoma IgGs for their activities as bispecific antibodies.
    Patke S; Li J; Wang P; Slaga D; Johnston J; Bhakta S; Panowski S; Sun LL; Junttila T; Scheer JM; Ellerman DA
    MAbs; 2017 Apr; 9(3):430-437. PubMed ID: 28125314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant approaches to IgG-like bispecific antibodies.
    Marvin JS; Zhu Z
    Acta Pharmacol Sin; 2005 Jun; 26(6):649-58. PubMed ID: 15916729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficient production of bispecific IgG of different isotypes and species of origin in single mammalian cells.
    Dillon M; Yin Y; Zhou J; McCarty L; Ellerman D; Slaga D; Junttila TT; Han G; Sandoval W; Ovacik MA; Lin K; Hu Z; Shen A; Corn JE; Spiess C; Carter PJ
    MAbs; 2017; 9(2):213-230. PubMed ID: 27929752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tetravalent anti-CD20/CD3 bispecific antibody for the treatment of B cell lymphoma.
    Lu CY; Chen GJ; Tai PH; Yang YC; Hsu YS; Chang M; Hsu CL
    Biochem Biophys Res Commun; 2016 May; 473(4):808-813. PubMed ID: 27040766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Production of bispecific antibodies in "knobs-into-holes" using a cell-free expression system.
    Xu Y; Lee J; Tran C; Heibeck TH; Wang WD; Yang J; Stafford RL; Steiner AR; Sato AK; Hallam TJ; Yin G
    MAbs; 2015; 7(1):231-42. PubMed ID: 25427258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.